PlainRecalls
FDA Drug Moderate Class II Terminated

Rufinamide Tablets, USP 400 mg, packaged in 120-count bottle, Rx only, Distributed by: Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520, Made in India, NDC 59651-617-08

Reported: August 30, 2023 Initiated: July 21, 2023 #D-1088-2023

Product Description

Rufinamide Tablets, USP 400 mg, packaged in 120-count bottle, Rx only, Distributed by: Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520, Made in India, NDC 59651-617-08

Reason for Recall

cGMP deviations: Batch was released prior to approval.

Details

Recalling Firm
Aurobindo Pharma USA Inc.
Units Affected
48 bottles
Distribution
USA nationwide
Location
East Windsor, NJ

Frequently Asked Questions

What product was recalled?
Rufinamide Tablets, USP 400 mg, packaged in 120-count bottle, Rx only, Distributed by: Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520, Made in India, NDC 59651-617-08. Recalled by Aurobindo Pharma USA Inc.. Units affected: 48 bottles.
Why was this product recalled?
cGMP deviations: Batch was released prior to approval.
Which agency issued this recall?
This recall was issued by the FDA Drug on August 30, 2023. Severity: Moderate. Recall number: D-1088-2023.